Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.

@article{Scheithauer2002RandomizedMP,
  title={Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.},
  author={Werner Scheithauer and Gabriela Verena Kornek and Markus Raderer and Herbert Ulrich-Pur and Wolfgang Fiebiger and Claudia Gedlicka and Birgit Schuell and S Terry Brugger and Bruno Schneeweiss and Fritz Lang and Alfred Lenauer and Dieter Depisch},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 1},
  pages={165-72}
}
PURPOSE Irinotecan and oxaliplatin are two new agents with promising activity in advanced colorectal cancer. Based on preclinical and clinical evidence that both drugs act synergistically, a randomized phase II study was initiated to investigate the therapeutic potential and tolerance of this combination in the front-line setting. PATIENTS AND METHODS Ninety-two patients with previously untreated, measurable disease were randomized to receive biweekly oxaliplatin 85 mg/m(2) plus irinotecan… CONTINUE READING